Dimethyl fumarate reduces relapse rate in MS

被引：0
|
作者：
不详
机构：
来源：
PROGRESS IN NEUROLOGY AND PSYCHIATRY | 2011年 / 15卷 / 03期
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [21] Dimethyl Fumarate Treatment Alters NK Cell Function in MS
    Smith, Matthew
    Calabresi, Peter A.
    Bhargava, Pavan
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 37 - 38
  • [22] Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS
    Granqvist, Mathias
    Burman, Joachim
    Gunnarsson, Martin
    Lycke, Jan
    Nilsson, Petra
    Olsson, Tomas
    Sundstrom, Peter
    Svenningsson, Anders
    Vrethem, Magnus
    Frisell, Thomas
    Piehl, Fredrik
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (12) : 1532 - 1539
  • [23] Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, Maryam
    Barilla, David
    Lee, Chieh-Hsin
    Blevins, Gregg
    Giuliani, Fabrizio
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2018, 5 (02):
  • [24] Natalizumab reduces relapse clinical severity and improves relapse recovery in MS
    Lublin, Fred D.
    Cutter, Gary
    Giovannoni, Gavin
    Pace, Amy
    Campbell, Nolan R.
    Belachew, Shibeshih
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2014, 3 (06) : 705 - 711
  • [25] Improved Gastrointestinal Tolerability Profile with Diroximel Fumarate Compared to Dimethyl Fumarate in Relapsing MS Patients
    Wundes, Annette
    Wolinsky, Jerry S.
    Wray, Sibyl
    Ziemssen, Tjalf
    Jasinska, Elzbieta
    Freedman, Mark S.
    Bidollari, Ilda
    Chen, Hailu
    Hanna, Jerome
    Leigh-Pemberton, Richard
    Lyons, Jennifer
    Messer, Jordan
    Naismith, Robert T.
    NEUROLOGY, 2020, 94 (15)
  • [26] Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors
    Zurawski, Jonathan
    Flinn, Ashley
    Sklover, Lindsay
    Sloane, Jacob A.
    JOURNAL OF NEUROLOGY, 2016, 263 (08) : 1511 - 1517
  • [27] Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors
    Jonathan Zurawski
    Ashley Flinn
    Lindsay Sklover
    Jacob A. Sloane
    Journal of Neurology, 2016, 263 : 1511 - 1517
  • [28] Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions
    Zinger, Nicole
    Ponath, Gerald
    Sweeney, Elizabeth
    Nguyen, Thanh D.
    Lo, Chih Hung
    Diaz, Ivan
    Dimov, Alexey
    Teng, Leilei
    Zexter, Lily
    Comunale, Joseph
    Wang, Yi
    Pitt, David
    Gauthier, Susan A.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (02):
  • [29] LC-MS/MS quantification of dimethyl fumarate and methyl hydrogen fumarate in rat blood using tiopronin as trapping reagent
    Junnotula, Venkatraman
    Licea-Perez, Hermes
    ANALYTICAL METHODS, 2016, 8 (34) : 6420 - 6427
  • [30] Safety of Dimethyl Fumarate in Japanese Patients with Relapse-remitting MS for 72 Weeks in the APEX Part 1 and Part 2 Studies
    Ochi, H.
    Niino, M.
    Onizuka, Y.
    Hiramatsu, K.
    Hase, M.
    Yun, J.
    Torii, S.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 456 - 456
12345